StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.97−0.03 (-0.04%)

Close on Nov 16, 2026Market cap $483.08MP/E –Yield –

Monopar Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Monopar Therapeutics's enterprise value was $376.09M on Nov 11, 2026, against $319.04M a year earlier. Over the last 5 years it ranged from -$10.35M to $645.92M, with a median of $18.72M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$376.09M+109.0%
2025Dec 31, 2025$179.92M+173.7%
2024Dec 31, 2024$65.74M–
2023Dec 29, 2023-$8.34M-151.6%
2022Dec 30, 2022$16.15M-10.6%
2021Dec 31, 2021$18.07M-65.3%
2020Dec 31, 2020$52.10M-65.2%
2019Dec 31, 2019$149.74M–

More Monopar Therapeutics figures

See a number that looks wrong?